CG Oncology, Inc. (CGON) vs Immunovant, Inc. (IMVT)
CG Oncology, Inc. and Immunovant, Inc. are both Biotechnology companies. Immunovant, Inc. is the larger, with a market value of $7.1B against $6.1B — 1.2× the size. Immunovant, Inc. has the higher net margin (0.00% vs −3,602.7%) and the higher return on invested capital (0.00% vs −4,111.6%). Across the 14 metrics below, Immunovant, Inc. leads on 8 and CG Oncology, Inc. on 6.
Valuation
Profitability
| Metric | CGON | IMVT | Biotechnology median |
|---|---|---|---|
| Gross margin | (85.20%) | 0.00% | 65.16% |
| Operating margin | (4,056.18%) | 0.00% | 0.00% |
| Net margin | (3,602.68%) | 0.00% | 0.00% |
| Free cash flow margin | (2,879.62%) | 0.00% | 0.00% |
| Return on equity | (26.41%) | (80.10%) | (57.72%) |
| Return on assets | (25.11%) | (71.10%) | (49.22%) |
| Return on invested capital | (4,111.64%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack